Mass General Brigham Cancer Institute

Immunotherapy

The Mass General Brigham Cancer Institute is committed to understanding the mechanisms by which the immune system works to kill cancer.
Electron microscope image of CAR T-cell interacting with tumor cell. Image courtesy of Maus lab.
Electron microscope image of CAR T-cell interacting with tumor cell. Image courtesy of Maus lab.
Electron microscope image of CAR T-cell interacting with tumor cell. Image courtesy of Maus lab.

Progress in Immunotherapy

Thanks to the hard work of researchers, we're getting smarter about cancer. Right now, we're finding ways to use the body's own immune system to manipulate genes to solve cancer's puzzle.

Learn more about car t-cell therapies.

CAR T-Cell Therapies

Mass General Brigham Cancer Institute is an authorized treatment center for FDA approved CAR T-cell therapies for adult patients with lymphoma and adult patients with multiple myeloma.

Learn about TIL Therapy for Melanoma

Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma

Mass General Brigham Cancer Institute is one of the first centers to provide TIL therapy to patients with advanced melanoma.

Learn more

CAR-T Therapy for Glioblastoma: INCIPIENT Trial

A collaborative project to bring the promise of cell therapy to patients with a deadly form of brain cancer has shown dramatic results among the first patients to receive the novel treatment.

Learn more about the Cellular Immunotherapy program.

Cellular Immunotherapy Program

The mission of the Cellular Immunotherapy Program is to invent, develop, administer, and understand engineered immune effector cells.

Learn more about the Center for Cancer Immunology.

Center for Cancer Immunology

The Center for Cancer Immunology’s investigators are working to expand the use of immunotherapy, a revolutionary approach to cancer therapy.

Severe Immunotherapy Complications Service

The Severe Immunotherapy Complications Service and Clinical-Translational Research Effort Program is working to address the urgent need to understand how and why immune-related adverse events occur.

Learn more
1 of 1

New CAR-T Therapy Shows Promise for Glioblastoma

A research team from the Mass General Brigham Cancer Institute recently conducted an early-stage trial of a new cell therapy for patients with recurrent glioblastoma. Preliminary results have shown remarkable initial responses among the first patients to receive the novel treatment.

Learn more
1 of 1

What is Immunotherapy?

Immunotherapy is a type of cancer treatment that uses the body’s immune system to find and attack cancer cells.

Learn more

What is immunotherapy and how is CAR T-cell therapy, a type of immunotherapy, used to treat multiple myeloma? Andrew Yee, MD explains what multiple myeloma is, and why CAR T-cell therapy is becoming a standard treatment for this rare blood cancer.

What is CAR T-Cell Therapy? How can we use the immune system to fight cancer? What are the latest advancements in cell therapy? Matthew Frigault, MD discusses how cells in the body can provide long-term protection against different types of cancer.

Gene therapy offers durable treatments that modify defective genetic material to combat disease, while cell therapy involves the transplantation of healthy cells to repair or replace damaged tissue. Together, these therapies aim to restore proper cellular and genetic functions.

Noopur Raje, MD, Marcela Maus, MD, PhD and Matthew Frigault, MD discuss the power and evolution of immune therapies, specifically, CAR T-Cell therapy in treating cancer.

Billy Costa talks with Dr. Matt Frigault and oncology social worker Lauren DeMarco to learn more about the latest in CAR- T-cell therapies and what it all means for patients.

Dr. Nir Hacohen sits down with Kiss 108's Billy Costa to discuss a researchers perspective of immuno-oncology and how it has impacted patients.

Dr. Justin Gainor summarizes immunotherapy and explains why people should know about these therapies. This video was recorded on May 17, 2019 at the Annual Advances in Cancer Immunotherapy CME Course.

In this presentation from July 8, 2021, Dr. Kerry Reynolds provides an immunotherapy overview. She also discusses the urgent need to understand how and why immune-related adverse events occur and how to best manage them.

Billy Costa of Kiss 108 Radio sits down with Dr. Kerry Reynolds and Dr. Chloe Villani to learn about the incredible team dynamic between research and clinical practice for patients at the Mass General Brigham Cancer Institute.

Kiss 108 FM’s Billy Costa talks with four experts from the Cancer Institute to learn about what CAR T-cell therapy is and what impact it has on both patients and the medical community.

1 of 10

Our goal is to understand how immune responses against tumors are initiated, maintained and evaded, with the hope of improving the ability of the immune system to eradicate cancer.

Nir Hacohen, PhD
Director, Center for Cancer Immunology, Mass General Brigham Cancer Institute

Explore more at Mass General Brigham Cancer Institute:

 

Contact the Cancer Institute

Contact the Mass General Brigham Cancer Institute to make an appointment or learn more about our programs.

Request an appointmentClinical trials617-726-5130